JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
Approved
DIN Number
02519461
Drug Class
Human
Market Date
Dec 14, 2022
Company
HC
Jamp Pharma Corporation
Product Information
Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.
Product Details
Health Canada regulatory and product classification information
Regulatory Identifiers
DIN Number02519461
AIG Number0352327001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
Product Specifications
Dosage FormTablet
Route of AdministrationOral
AHFS Classification08:18.08.16
Health Canada Classification
ACTIVE INGREDIENTS (3)
EFAVIRENZActive
Strength: 600 MG
Monograph: EFAVIRENZ
EMTRICITABINEActive
Strength: 200 MG
Monograph: EMTRICITABINE
TENOFOVIR DISOPROXIL FUMARATEActive
Strength: 300 MG
Monograph: TENOFOVIR DISOPROXIL FUMARATE